Skip to main content
. Author manuscript; available in PMC: 2021 Apr 20.
Published in final edited form as: Acc Chem Res. 2020 Oct 5;53(10):2094–2105. doi: 10.1021/acs.accounts.0c00456

Figure 2.

Figure 2.

(A) Schematic illustration of RGO-based cancer nanovaccine. Shown are the structure of RGO(CpG)-PEG-neoantigen and its proposed mechanism of LN draining and ROS-enhanced antigen presentation. (B) PET imaging of 64Cu-NOTA-Adpgk + CpG and 64Cu-NOTA-RGO(CpG)-PEG-Adpgk after SC injection. (C) Treatment regimen and overall survival curve for MC-38 tumor therapeutic vaccine study. (D) Frequencies of Adpgk-specific CD8α+ T cells and the average tumor growth curves in the MC-38 tumor model. Reproduced with permission from ref 2. Copyright 2020 American Chemical Society.